| Literature DB >> 30537212 |
Richard J Lin1, Caleb Ho2, Patrick D Hilden3, Juliet N Barker1,4, Sergio A Giralt1,4, Paul A Hamlin5,4, Ann A Jakubowski1,4, Hugo R Castro-Malaspina1,4, Kevin S Robinson1, Esperanza B Papadopoulos1,4, Miguel-Angel Perales1,4, Craig S Sauter1,4.
Abstract
TP53 alterations portend extremely poor prognosis in patients with mantle cell lymphoma treated with standard treatment modalities. We reviewed outcomes of 42 patients with available TP53 status who had received a reduced-intensity or non-myeloablative allogeneic haematopoietic cell transplant at our institution. We demonstrated a 2-year overall survival and progression-free survival of 78% [95% confidence interval (CI) 60-88] and 61% (95% CI 43-75), respectively. The 2-year cumulative incidences of relapse and non-relapse mortality were 19% and 20%, respectively. Importantly, there is no significant difference among patients with and without TP53 alterations, suggesting for the first time a beneficial treatment modality for these high-risk patients.Entities:
Keywords: zzm321990TP53zzm321990; allogeneic hematopoietic cell transplant; mantle cell lymphoma
Mesh：
Substances：
Year: 2018 PMID： 30537212 PMCID： PMC6399037 DOI： 10.1111/bjh.15721
Source DB: PubMed Journal: Br J Haematol ISSN： 0007-1048 Impact factor: 6.998